Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 2024-12-06			5-day change	1st Jan Change
180,100.00 ^KRW	-0.50%		-3.69%	-10.62%

Dec. 05	Celltrion to Retire 3 Million Treasury Stock in January	MT
Dec. 04	South Korea's FTC Slaps KRW435 Million Fine on Celltrion for Unfair Business Practices	MT

Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on October 23, 2023.

November 08, 2023

From October 23, 2023 to November 7, 2023, the company has repurchased 2,426,161 shares, representing 1.71% for KRW 365,096.41 million. With this, the company has completed the repurchase of 2,426,161 shares, representing 1.71% for KRW 365,096.41 million under the buyback announced on October 23, 2023.

Latest news about Celltrion, Inc.

Celltrion to Retire 3 Million Treasury Stock in January	Dec. 04	MT
South Korea's FTC Slaps KRW435 Million Fine on Celltrion for Unfair Business Practices	Dec. 03	MT
Celltrion, Inc. - Analyst/Investor Day	Nov. 27
Celltrion Launches KRW100 Billion Share Buyback	Nov. 22	MT
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on October 25, 2024.	Nov. 20	CI
Celltrion, Inc.'s Equity Buyback announced on October 25, 2024, has closed with 537,924 shares, representing 0.26% for KRW 94,709.84 million.	Nov. 18	CI
Celltrion Presents Additional Data from Phase III Randomized Controlled Trials to Further Support Biosimilarity for CT-41 (Biosimilar Candidate of Denosumab) and CT-P47 (Biosimilar Candidate of Tocilizumab) At American College of Rheumatology Convergence 2024	Nov. 18	CI
Celltrion to Acquire iQone Healthcare Switzerland in European Expansion Push	Nov. 14	MT
Celltrion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 14	CI
Trump makes Wall Street shine and depresses Europe	Nov. 11
South Korean Shares Slide as Investors Remain Wary of New US Economic Policies After Trump Win	Nov. 11	MT
Celltrion's Net Attributable Income Plunges 61% in Q3, Sales Up 31%	Nov. 10	MT
Celltrion's Zymfentra Gains Broad US Insurance Coverage with New PBM Agreement	Oct. 29	MT
Celltrion's Zymfentra Monotherapy Shows Comparable Efficacy to Combo Therapy in IBD Study	Oct. 29	MT
Celltrion to Carry Out Share Buyback to Boost Value	Oct. 27	MT
Celltrion, Inc. announces an Equity Buyback for 537,924 shares.	Oct. 24	CI
Celltrion, Inc. authorizes a Buyback Plan.	Oct. 24	CI
Celltrion Signs Migraine Drug Development Deal with TEVA Pharmaceuticals	Oct. 21	MT
Celltrion Launches New Cell Line Platform for Biopharmaceutical Efficiency Boost	Oct. 16	MT
Celltrion Presents IBD Drug Data at European Gastroenterology Conference	Oct. 16	MT
Celltrion Presents 2-Year Post-Hoc Analysis Findings for Subcutaneous Infliximab (CT-P13 SC), Highlighting Dose Escalation as an Option for Managing Loss of Response in Inflammatory Bowel Disease	Oct. 15	CI
Celltrion Secures Five-Year Cancer Drug Supply Deal from Brazil	Sep. 16	MT
Celltrion Usa Partners with Express Scripts and Cigna Healthcare to Expand Access to Zymfentra® (Infliximab-Dyyb), the First and Only Fda-Approved Subcutaneous Infliximab on Their Medical Benefit Formulary	Aug. 28	CI
European Commission Approves Celltrion's SteQeyma (CT-P43) A Biosimilar to Stelara (ustekinumab), for the Treatment of Multiple Chronic Inflammatory Diseases	Aug. 25	CI
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on June 14, 2024.	Aug. 25	CI

Chart Celltrion, Inc.

Duration

Period

A068270: Dynamic Chart

Company Profile

Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.

Employees

2,391

Sector

Biotechnology & Medical Research

Calendar

2025-04-06 - Q4 2024 Earnings Release (Projected)

More about the company